DRMAW
Dermata Therapeutics, Inc. Warrant
stock NASDAQ Warrant

DRM, low float buy when unhalt !
# BREAKING: Dermata's XYNGARI™ Phase 3 Trial Topline Data Meets All Primary Endpoints
**Thursday, 27****^(th)** **March at 8:00 am**
*- XYNGARI™ achieved its primary endpoints, demonstrating highly statistically significant and clinically meaningful improvement in acne -*
*- XYNGARI™ is the first once-weekly topical product candidate to demonstrate clinical benefit in a Phase 3 clinical trial for moderate-to-severe acne* \-
*- Over 30 million acne patients seek treatment in the U.S. each year -*
SAN DIEGO, March 26, 2025 /PRNewswire/ -- [Dermata Therapeutics, Inc.](https://c212.net/c/link/?t=0&l=en&o=4392681-1&h=1814492621&u=https%3A%2F%2Fwww.dermatarx.com%2F&a=Dermata+Therapeutics%2C+Inc.) (NASDAQ: DRMA, DRMAW)) ("Dermata" or the "Company"), a late-stage biotechnology company focusing on the treatment of medical skin diseases and aesthetic applications, today announced positive topline results from the Company's first pivotal Phase 3 trial of XYNGARI™, a novel, once-weekly, topical product candidate for the treatment of moderate-to-severe acne. XYNGARI^(TM) also appeared to be safe and well tolerated by patients with minimal treatment related adverse events and no serious adverse events attributed to treatment.
The XYNGARI™ Phase 3 **S**pongilla **T**reatment for **A**cne **R**esearch (STAR-1) trial met all three primary endpoints by achieving a statistically significant difference when compared with placebo after 12 weeks of once weekly treatments with XYNGARI™.
"I believe having a once-weekly topical product with a strong efficacy and safety profile, like XYNGARI™, would be a great addition to a dermatologist's arsenal for treating acne," commented Dr. Sunil Dhawan, MD, FAAD, FACP, clinical investigator at the Center for Dermatology Clinical Research, Inc., a participating site in the STAR-1 trial. "All FDA approved topical acne products are required to be applied at least once or twice a day, which may reduce patient compliance, so I believe having a once-weekly topical acne product like XYNGARI™ could lead to improved patient compliance," concluded Dr. Dhawan.
"We are incredibly excited about these Phase 3 clinical trial results for XYNGARI™, which we believe reinforce its potential as a unique acne treatment, distinct from any existing product on the market," said Gerry Proehl, Chairman, President, and Chief Executive Officer of Dermata. "The highly statistically significant efficacy data not only confirms the results of our Phase 2b acne study but also strengthens our confidence about the upcoming XYNGARI™ Phase 3 STAR-2 trial, set to launch in the second half of 2025. With these positive Phase 3 clinical trial results, we are eager to advance discussions with potential partners interested in securing future rights to XYNGARI™," Mr. Proehl added.BREAKING: Dermata's XYNGARI™ Phase 3 Trial Topline Data Meets All Primary Endpoints

DRM, low float buy when unhalt !
# BREAKING: Dermata's XYNGARI™ Phase 3 Trial Topline Data Meets All Primary Endpoints
**Thursday, 27****^(th)** **March at 8:00 am**
*- XYNGARI™ achieved its primary endpoints, demonstrating highly statistically significant and clinically meaningful improvement in acne -*
*- XYNGARI™ is the first once-weekly topical product candidate to demonstrate clinical benefit in a Phase 3 clinical trial for moderate-to-severe acne* \-
*- Over 30 million acne patients seek treatment in the U.S. each year -*
SAN DIEGO, March 26, 2025 /PRNewswire/ -- [Dermata Therapeutics, Inc.](https://c212.net/c/link/?t=0&l=en&o=4392681-1&h=1814492621&u=https%3A%2F%2Fwww.dermatarx.com%2F&a=Dermata+Therapeutics%2C+Inc.) (NASDAQ: DRMA, DRMAW)) ("Dermata" or the "Company"), a late-stage biotechnology company focusing on the treatment of medical skin diseases and aesthetic applications, today announced positive topline results from the Company's first pivotal Phase 3 trial of XYNGARI™, a novel, once-weekly, topical product candidate for the treatment of moderate-to-severe acne. XYNGARI^(TM) also appeared to be safe and well tolerated by patients with minimal treatment related adverse events and no serious adverse events attributed to treatment.
The XYNGARI™ Phase 3 **S**pongilla **T**reatment for **A**cne **R**esearch (STAR-1) trial met all three primary endpoints by achieving a statistically significant difference when compared with placebo after 12 weeks of once weekly treatments with XYNGARI™.
"I believe having a once-weekly topical product with a strong efficacy and safety profile, like XYNGARI™, would be a great addition to a dermatologist's arsenal for treating acne," commented Dr. Sunil Dhawan, MD, FAAD, FACP, clinical investigator at the Center for Dermatology Clinical Research, Inc., a participating site in the STAR-1 trial. "All FDA approved topical acne products are required to be applied at least once or twice a day, which may reduce patient compliance, so I believe having a once-weekly topical acne product like XYNGARI™ could lead to improved patient compliance," concluded Dr. Dhawan.
"We are incredibly excited about these Phase 3 clinical trial results for XYNGARI™, which we believe reinforce its potential as a unique acne treatment, distinct from any existing product on the market," said Gerry Proehl, Chairman, President, and Chief Executive Officer of Dermata. "The highly statistically significant efficacy data not only confirms the results of our Phase 2b acne study but also strengthens our confidence about the upcoming XYNGARI™ Phase 3 STAR-2 trial, set to launch in the second half of 2025. With these positive Phase 3 clinical trial results, we are eager to advance discussions with potential partners interested in securing future rights to XYNGARI™," Mr. Proehl added.BREAKING: Dermata's XYNGARI™ Phase 3 Trial Topline Data Meets All Primary Endpoints